Ab Kabi

Kabivitrum Ab

Gunnar Hanshoff

Ferenc Merenyi

Lennart E Karlsson

Pinchas Moses

Lars-Olov Andersson

Carl Magnus Svahn

Aake N Joensson

Goran Lindroos

Elisabeth Charlotte Carling Nee Ehrenberg

Nanna Forsman

Hakan Gunnar Borg

Maggie Miller-Andersson

Novel antifibrinolytically active compounds of the formula ##STR1## and therapeutically acceptable salt thereof, wherein

Antifibrinolytically active derivatives of tranexamic acid

New compounds of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 each independently represent an alkyl group containing 1 to 4 carbon atoms, or an alkoxy group containing 1 to 3 carbon atoms, or halogen, R.sup.3 represents hydrogen, halogen, an alkyl group containing 1 to 4 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, an amino group or a nitro group, A represents ##STR2## which is bonded to the benzene ring by its sulphur or nitrogen atom and in which R.sup.4 is hydrogen or an alkyl group containing 1 to 4 carbon atoms; together with salts thereof with physiologically acceptable acids and, when R.sup.4 is hydrogen, with physiologically acceptable bases are described. The compounds are of use in inhibiting thrombosis formation, in treating thrombosis and in fibronolytic therapy. Various methods of producing the new compounds are described involving the building up of the --A--CH.sub.2 --CH.sub.2 --S--CH.sub.2 CH.sub.2 NH.sub.2 side chain from aromatic precursors having an incomplete side chain or by introducing at least one of the R.sup.1, R.sup.2 or R.sup.3 substituents into a precursor lacking that substituent or from an amino-protected precursor.

Anti-thrombotic N-alkylthioakylamino benzenesulfonamides

The blood coagulation factors I (fibrinogen) and VIII (antihemophilia factor, abbreviated AHF) are isolated in high yields from animal tissue materials such as blood or blood products (e.g. plasma) or plasma fractions by a procedure involving the essential step of adsorption (as in affinity chromatography) of at least one of these factors, in a liquid system, onto a water-insoluble gel matrix primarily composed of a cross-linked sulfated or sulfonated, gel-forming carbohydrate such as cross-linked dextran sulfate-agarose, cross-linked dextran sulfate-dextran, cross-linked heparin-agarose and other such gel matrix-providing substances.

Isolation of coagulation factors I and VIII from biological material

Growing community of inventors

Jaerfaella, Sweden

Gunnar Hanshoff